Gail Connor Roche

A review of literature on depression and anxiety in patients with heart failure reports that 21.5% have depressive symptoms and 19% meet the criteria for a depressive disorder—2 to 3 times higher than rates in the general population.

Holidays and special events can cause increased likelihood of status epilepticus, possibly due to alcohol consumption and withdrawal, changes in sleep patterns, and non-compliance with anti-seizure drugs.

The newly-revealed structure of the neurotransmitter GABAA, a γ-aminobutyric acid, opens new possibilities for drugs to treat epilepsy, anxiety, and insomnia.

Previously, the benefit of exercise in mediating both CVD and depression was documented, but the association between midlife fitness with later depression and death from heart disease had not been.

Between 2013 and 2016, diagnoses of major depression jumped by 33% overall, and by 63% and 47% among adolescents and millennials, respectively.

The authors found no studies supporting the use of alternative treatments, such as cognitive behavioral therapy or omega fatty acids, over ADHD medications.

Depression in men–but not women–reduces the chances of pregnancy for infertile couples, a new study suggests.

Researchers in Baltimore found a connection between prenatal complications, genetic risk, and the impact on neurodevelopmental conditions in children.

Within 6 months, clinicians with access to the test results were 1.44 times more likely to have diagnosed or excluded ADHD.

On average, shorter gaps in care were not detrimental to patient viral load status, though certain subgroups of patients may benefit from more frequent viral load monitoring.

The prevalence of disordered eating in the general population is 12%, but individuals with ADHD may face greater risks.

Analyzing post-mortem brain tissue of subjects with major depressive disorder, researchers found that 52 genes were expressed differently in women and men.

The drug is approved for adults with depression, but exceptionally high placebo responses rendered its effects in children not statistically significant.

The clinically relevant findings suggest that infant passive immunization with second-generation broad and potent bNAbs could be an effective strategy to block mother-to-child HIV transmission.

These findings provide health care decision-makers with novel information about the allocation of scarce resources relating to Clostridium difficile.

Teens who self-reported inattention, hyperactivity/impulsivity, and conduct disorder also reported higher risky driving behaviors.

Patients using statins had a 4.3% infection rate compared with a 7.8% rate for those not taking statins, concluding that statins may be associated with a 20% risk reduction.

The team found that the children with both conditions had 2.2 times the risk of anxiety disorder and 2.7 times the risk of other mood disorders.

Findings suggest that proline and proline-rich metabolites such as trans-4-hydroxyproline are very important for growth during the early stages of C. difficile colonization.

This research contradicts previous TDF studies that were not placebo-controlled.

The odds of reaching undetectable HCV RNA by 12 weeks were 57% less for African-Americans in the retrospective study.

Researchers isolated the neurotoxic complex crotoxin from the venom of Crotalus durissus terrificus, commonly known as the South American rattlesnake.

More than 75% of hepatitis C patients suffer from conditions beyond the kidney. A roundtable group is trying to spread that fact.

Approximately 44.7% of the patients with FMS screened positive for adult ADHD.

Acute hepatitis C cases rose 133% from 2004 to 2014, while admissions to substance use disorder treatment facilities for opioid injections climbed 93%.

Maternal HCV infections at the time of a baby’s delivery almost doubled to 3.4 per 1000 live births in 2014, from 1.8 per 1000 in 2009.

Improvement in early screening, the development of biomarkers and therapy testing will change the screening process for autism and ADHD.

The CFDA approved Gilead’s sofosbuvir for use as standalone drug or as part of a combination treatment in September 2017.

The study suggests those with different types of ADHD have impairments in unique brain systems.

Researchers found that viral load can predict SVR rates nearly 1 month into DAA therapy.